First Woman in Europe Joins Group B Strep Vaccine Trial to Save Babies

Menna Hulme, a mother from English Frankton in north Shropshire, became the first woman in Europe to join a clinical trial for a Group B Streptococcus vaccine during her pregnancy. The trial, led by Professor Will Parry-Smith from Keele University, aims to protect newborns from an infection that affects one in 1,750 babies in the UK and kills one a week. Babies can contract the bacteria by ingesting it while passing through the birth canal, making the development of a preventative vaccine a significant potential milestone for maternal and neonatal health.

Group B Streptococcus Risks and Current Treatment Limits in the UK

During her first pregnancy five years ago, Hulme received intravenous antibiotics during labor as a precautionary measure after testing positive for Group B Streptococcus. The mother described feeling uncertain and daunted by the diagnosis after small traces were flagged during a urine test at her initial midwife appointment. Because the UK does not feature routine screening for the bacteria, detection often happens by chance during early prenatal care. For her second pregnancy, Hulme delivered via Caesarean section to reduce transmission risks, and she gave birth to her third child in January at 9 pounds 6 ounces without health complications. With your first pregnancy, you are a bit naive about everything, so you have to go by what healthcare professionals tell you and advise you, she said, adding that finding out about the bacteria 12 to 16 weeks into a first pregnancy leaves a mother pretty daunted by it. She noted that there is not much you can actually do about it during labor other than take the preventative antibiotics. I was a first-time mum, wanting to have as much of a natural labour as I could, she explained, noting that IV antibiotics were not what she wanted but was the safest option.

Hulme Joins World-First Vaccine Trial During Pregnancy

Expecting her third child, Hulme learned about the world-first vaccine trial led by Parry-Smith and received the immunization at the Princess Royal Hospital in Telford at 34 weeks of gestation. After discussing what was involved in the study, she felt reassured that it was as safe as can be for me and stated that we were as safe as we could be with doing this trial vaccine. Being the first participant meant she could not observe how other patients had fared, but she emphasized that GBS itself has plenty of risks involved anyway and quite serious illnesses with babies. The National Institute for Health and Care Research records approximately 4,000 deliveries a year from GBS-positive mothers at Shrewsbury and Telford Hospitals NHS Trust, alongside more than 60,000 across the wider West Midlands. Parry-Smith noted that the local population in Shropshire demonstrates a strong willingness to participate in medical research and vaccine studies due to established community engagement through midwives and hospital open days, adding that researchers were very privileged to have not just Menna, but many women in Shropshire who selflessly will take part in research in order to drive care for future pregnant mothers and families.

Researchers Aim for Global Vaccine to Prevent Infant Deaths

Researchers intend for the trial to yield a widely available vaccine that could prevent infant deaths and stillbirths both domestically and internationally. Hulme stated that she hopes her participation will pave the way for a widely available vaccine to protect families worldwide during childbirth.